TR201809050T4 - Sızan afinite arındırma ligandının giderilmesi. - Google Patents

Sızan afinite arındırma ligandının giderilmesi. Download PDF

Info

Publication number
TR201809050T4
TR201809050T4 TR2018/09050T TR201809050T TR201809050T4 TR 201809050 T4 TR201809050 T4 TR 201809050T4 TR 2018/09050 T TR2018/09050 T TR 2018/09050T TR 201809050 T TR201809050 T TR 201809050T TR 201809050 T4 TR201809050 T4 TR 201809050T4
Authority
TR
Turkey
Prior art keywords
protein
nacl
chromatography
condition
proteins
Prior art date
Application number
TR2018/09050T
Other languages
English (en)
Turkish (tr)
Inventor
Ray Trejo Samuel
Perry Brake Robert
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50424772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201809050(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of TR201809050T4 publication Critical patent/TR201809050T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TR2018/09050T 2013-03-14 2014-03-11 Sızan afinite arındırma ligandının giderilmesi. TR201809050T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
TR201809050T4 true TR201809050T4 (tr) 2018-07-23

Family

ID=50424772

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/09050T TR201809050T4 (tr) 2013-03-14 2014-03-11 Sızan afinite arındırma ligandının giderilmesi.

Country Status (17)

Country Link
US (3) US20160024144A1 (enExample)
EP (3) EP3395423B1 (enExample)
JP (1) JP6457479B2 (enExample)
AU (1) AU2014240596B2 (enExample)
CA (1) CA2904411A1 (enExample)
CY (1) CY1120353T1 (enExample)
DK (2) DK2969099T4 (enExample)
ES (2) ES2674697T5 (enExample)
FI (1) FI3395423T3 (enExample)
HU (2) HUE038565T2 (enExample)
LT (2) LT3395423T (enExample)
MX (2) MX365501B (enExample)
PL (2) PL2969099T5 (enExample)
PT (2) PT2969099T (enExample)
SI (2) SI3395423T1 (enExample)
TR (1) TR201809050T4 (enExample)
WO (1) WO2014159441A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3395423B1 (en) 2013-03-14 2023-09-20 Amgen Inc. Removal of leaked affinity purification ligand
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
BR112016029157A8 (pt) * 2014-06-13 2021-07-06 Lupin Ltd processo para purificar a proteína de fusão tnfr:fc
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
EP3436473A4 (en) * 2016-03-29 2019-10-23 Navya Biologicals Pvt. Ltd. METHOD FOR PURIFYING FC FUSION PROTEINS
EP3580231A1 (en) * 2017-02-09 2019-12-18 Bracco Suisse SA Process for the purification of soluble psgl-1 protein variants
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
KR101004174B1 (ko) 1995-06-29 2010-12-24 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
JP2000513394A (ja) 1996-06-21 2000-10-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ポリアミドの重合性誘導体
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2002505006A (ja) 1997-06-18 2002-02-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 分取クロマトグラフィーによる分離のためのモノリシック吸着剤の使用
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
WO2003059935A2 (en) * 2001-12-21 2003-07-24 Immunex Corporation Methods for purifying protein
KR101482791B1 (ko) * 2005-03-11 2015-01-21 와이어쓰 엘엘씨 약한 분배성 크로마토그래피법
EP2738178A1 (en) * 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
KR101523782B1 (ko) * 2006-11-08 2015-05-28 와이어쓰 엘엘씨 세포 배양을 위한 합리적으로 설계된 배지
KR20110091678A (ko) * 2008-10-20 2011-08-12 아보트 러보러터리즈 단백질 ａ 친화성 크로마토그래피를 이용한 항체의 분리 및 정제
RU2011137030A (ru) * 2009-03-11 2013-04-20 УАЙТ ЭлЭлСи Способы очистки малых модулярных иммунофармацевтических белков
EP2598515B1 (en) * 2010-07-30 2016-09-21 Pfizer Inc Tandem purification of proteins
WO2012176158A1 (en) 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
CN103814044A (zh) * 2011-07-08 2014-05-21 默沙东公司 纯化fc-融合蛋白的方法
KR102052774B1 (ko) * 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
EP3395423B1 (en) * 2013-03-14 2023-09-20 Amgen Inc. Removal of leaked affinity purification ligand

Also Published As

Publication number Publication date
HUE064450T2 (hu) 2024-03-28
PL2969099T3 (pl) 2018-10-31
HUE038565T2 (hu) 2018-10-29
MX365501B (es) 2019-06-05
MX391507B (es) 2025-03-21
JP2016513643A (ja) 2016-05-16
FI3395423T3 (fi) 2023-11-02
ES2674697T3 (es) 2018-07-03
EP3395423A1 (en) 2018-10-31
ES2964601T3 (es) 2024-04-08
WO2014159441A1 (en) 2014-10-02
EP2969099A1 (en) 2016-01-20
MX2019006568A (es) 2019-08-22
US20220144886A1 (en) 2022-05-12
JP6457479B2 (ja) 2019-01-23
PT3395423T (pt) 2023-11-14
US20190085021A1 (en) 2019-03-21
PL3395423T3 (pl) 2024-03-18
US20160024144A1 (en) 2016-01-28
EP3395423B1 (en) 2023-09-20
CA2904411A1 (en) 2014-10-02
US11492372B2 (en) 2022-11-08
MX2015011994A (es) 2015-12-01
EP2969099B2 (en) 2021-12-22
AU2014240596B2 (en) 2018-09-27
HK1220159A1 (en) 2017-04-28
EP2969099B1 (en) 2018-04-25
SI2969099T2 (sl) 2022-04-29
DK2969099T4 (da) 2022-03-14
DK3395423T3 (da) 2023-11-20
AU2014240596A1 (en) 2015-09-24
SI2969099T1 (sl) 2018-09-28
ES2674697T5 (es) 2022-04-19
PT2969099T (pt) 2018-07-05
US11192919B2 (en) 2021-12-07
EP4026596A1 (en) 2022-07-13
PL2969099T5 (pl) 2022-06-13
LT2969099T (lt) 2018-09-10
SI3395423T1 (sl) 2023-12-29
DK2969099T3 (en) 2018-07-09
CY1120353T1 (el) 2019-07-10
LT3395423T (lt) 2023-12-11

Similar Documents

Publication Publication Date Title
US11492372B2 (en) Removal of leaked affinity purification ligand
US9957318B2 (en) Protein purification methods to reduce acidic species
EP3116891B1 (en) Immunoglobulin purification using pre-cleaning steps
US20120141497A1 (en) Methods of purifying small modular immunopharmaceutical proteins
WO2013176754A9 (en) Novel purification of antibodies using hydrophobic interaction chromatography
KR20210149089A (ko) 사전 포획 응집을 이용하는 것에 의한 면역글로불린의 친화성 크로마토그래피 개선
Capela et al. Monoclonal Antibodies Addressing the Challenges on the Manufacturing Processing of an Advanced Class of Therapeutic Agents
HK40072589A (en) Removal of leaked affinity purification ligand
HK1220159B (en) Removal of leaked affinity purification ligand